Biotron Inkomsten in het verleden

Verleden criteriumcontroles 0/6

Biotron's earnings have been declining at an average annual rate of -2.6%, while the Biotechs industry saw earnings growing at 12.6% annually. Revenues have been growing at an average rate of 22.9% per year.

Belangrijke informatie

-2.6%

Groei van de winst

6.0%

Groei van de winst per aandeel

Biotechs Groei van de industrie9.6%
Inkomstengroei22.9%
Rendement op eigen vermogenn/a
Nettomarge-208.9%
Laatste winstupdate30 Jun 2024

Recente prestatie-updates uit het verleden

Geen updates

Recent updates

Here's Why We're Not Too Worried About Biotron's (ASX:BIT) Cash Burn Situation

Feb 27
Here's Why We're Not Too Worried About Biotron's (ASX:BIT) Cash Burn Situation

We Think Biotron (ASX:BIT) Can Afford To Drive Business Growth

Oct 20
We Think Biotron (ASX:BIT) Can Afford To Drive Business Growth

We're Not Worried About Biotron's (ASX:BIT) Cash Burn

Jul 06
We're Not Worried About Biotron's (ASX:BIT) Cash Burn

Will Biotron (ASX:BIT) Spend Its Cash Wisely?

Jan 18
Will Biotron (ASX:BIT) Spend Its Cash Wisely?

Will Biotron (ASX:BIT) Spend Its Cash Wisely?

Jul 06
Will Biotron (ASX:BIT) Spend Its Cash Wisely?

Here's Why We're Watching Biotron's (ASX:BIT) Cash Burn Situation

Mar 17
Here's Why We're Watching Biotron's (ASX:BIT) Cash Burn Situation

Here's Why We're Not Too Worried About Biotron's (ASX:BIT) Cash Burn Situation

Nov 27
Here's Why We're Not Too Worried About Biotron's (ASX:BIT) Cash Burn Situation

Biotron (ASX:BIT) Is In A Good Position To Deliver On Growth Plans

May 26
Biotron (ASX:BIT) Is In A Good Position To Deliver On Growth Plans

We're Not Very Worried About Biotron's (ASX:BIT) Cash Burn Rate

Feb 10
We're Not Very Worried About Biotron's (ASX:BIT) Cash Burn Rate

What Can We Conclude About Biotron's (ASX:BIT) CEO Pay?

Dec 19
What Can We Conclude About Biotron's (ASX:BIT) CEO Pay?

Opbrengsten en kosten

Hoe Biotron geld verdient en uitgeeft. Gebaseerd op laatst gerapporteerde winst, op LTM-basis.


Inkomsten en omzetgeschiedenis

ASX:BIT Opbrengsten, kosten en inkomsten (AUD Millions )
DatumInkomstenInkomstenG+A UitgavenR&D-uitgaven
30 Jun 242-314
31 Mar 242-414
31 Dec 232-414
30 Sep 232-424
30 Jun 231-323
31 Mar 232-313
31 Dec 223-213
30 Sep 222-213
30 Jun 222-313
31 Mar 221-313
31 Dec 211-313
30 Sep 211-313
30 Jun 211-313
31 Mar 211-413
31 Dec 201-413
30 Sep 201-413
30 Jun 201-413
31 Mar 200-312
31 Dec 190-312
30 Sep 191-312
30 Jun 191-211
31 Mar 191-211
31 Dec 181-211
30 Sep 181-211
30 Jun 182-212
31 Mar 182-112
31 Dec 173-113
30 Sep 172-213
30 Jun 172-313
31 Mar 172-313
31 Dec 162-212
30 Sep 162-313
30 Jun 162-313
31 Mar 162-313
31 Dec 152-313
30 Sep 152-313
30 Jun 152-313
31 Mar 152-313
31 Dec 142-313
30 Sep 142-313
30 Jun 142-313
31 Mar 141-413
31 Dec 131-414

Kwaliteitswinsten: BIT is currently unprofitable.

Groeiende winstmarge: BIT is currently unprofitable.


Analyse vrije kasstroom versus winst


Analyse van de winstgroei in het verleden

Winsttrend: BIT is unprofitable, and losses have increased over the past 5 years at a rate of 2.6% per year.

Versnelling van de groei: Unable to compare BIT's earnings growth over the past year to its 5-year average as it is currently unprofitable

Winst versus industrie: BIT is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (2.5%).


Rendement op eigen vermogen

Hoge ROE: BIT's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.


Rendement op activa


Rendement op geïnvesteerd vermogen


Ontdek sterk presterende bedrijven uit het verleden